> Assays per cell type > Human Mesenchymal Stromal Cells (hMSCs)

Which genomic assay when working on human Mesenchymal Stromal Cells (hMSCs)

Genomic stability in Mesenchymal Stromal Cells (MSCs) can be altered during their time in culture, raising issues. It can significantly reduce the cells’ differentiation potential, or have a detrimental impact on their therapeutic properties. It can also potentially impact patient safety in the long term (Neri, 2019).

G-Banding karyotyping is the gold standard for detecting abnormalities in mesenchymal stromal cells and provides a comprehensive assessment (balanced and unbalanced translocations, deletions, insertions and inversions).

However, if you need a faster solution at a lower cost, digital PCR can be an interesting alternative.

Detect over 80% of recurrent abnormalities in hMSCs in record-breaking time !

Confidently detect mycoplasma in any human cell culture

Recommended testing guidelines

According to Torre M L et al., the quality control process should be planned during the validation phase, during production and at batch release (Torre ML et al. 2017). This will ensure optimized MSC in-vitro culture conditions.

Definition

Mesenchymal Stromal Cells (MSCs) are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT).

They are also known as stromal/stem cells, medicinal signalling cells or in relation with their source, for instance “adipose-derived regenerative cells”.

History

In the 1960s, Friedenstein et al. identified a population of fibroblast-like cells that formed clonal colonies in vitro (CFU-F, Colony Forming Unit-Fibroblast) Friedenstein’s observations allowed for the discovery of a specific type of cell, currently referred to as mesenchymal stem cells (MSCs). MSCs are primary, non-specialized, non-hematopoietic, plastic-adherent cells with great proliferation potential and the capacity for self-renewal and differentiation. Source: Musiał-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019 Jul.

A flexible approach to meet variable needs

Stem Genomics recognizes the variety of needs coming from MSC laboratories. We have therefore designed an offer that not only meets your genomic detection needs, but also takes into account varying budget, performance and timescales expectations.

List of Stem Genomics’ human Mesenchymal Stromal Cell dedicated assays:

iCS-digital™ MSC range: Available in 24 probes, this unique test enables up to 80% detection of the most frequent genomic abnormalities in human mesenchymal stromal cells (hMSCs) in 3 days’ turnaround time. Available as a service only. More on iCS-digital™ MSC.